HERCULES portfolio: weekly course valuationHERCULES’ mid-term trend chart is presented.
Also the mid-term trend charts of the stocks that make up the portfolio are presented. ___
Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile.
Disclaimer
The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only.
It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances,
it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
A copy of the text on the chart follows:
---------------------------------------------------
HERCULES portfolio: weekly course valuation
15.6% rebound
* In my previous week's portfolio valuation I mentioned that a rising reaction was probable and
that it should be considered as a chance to sell in higher prices. I noted also that this guideline
will change only if the prices cross upwards the 30d, 50d and the 200d SMAs.
* Notice that as soon as the RSI reached its oversold area we had a rising reaction of 15.6%.
However, the MACD (which is in negative area) has not yet crossed its signal upwards.
* If the portfolio price overcomes the resistance zone R and remain for 2-3 days over the 30d SMA
then we have to buy back the stocks that will follow this move (if their price is over the 200d SMA too).
* If the portfolio price fails to brake the strong resistance zone R then a sharp fall (even with a gap)
is probable.
* With the exception of ERIC, all the other stock prices of the initial portfolio (MRNA, INO, ZM, HFG
and CRSR) are below both the 30d and the 50d SMAs. INO's and ZM's price is below the 200d SMA too.
CRSR's price is below the 200(10h) SMA (the 200d SMA is not yet defined because it's a recent IPO).
* In general, we remain very cautious and closely monitor the market in the coming days, because
many index-heavy stocks are close to critical support levels that if they break down, will cause panic
and a sharp decline.
* This HERCULES' portfolio analysis and all the previous ones, apply to all the portfolios with popular
Nasdaq stocks and the new traders should follow these analyses, because they are an application
of the method described in my post "You can't beat the market", until they don't need these
analyses anymore because they'll do their own.
------------------------------------------------------------------------------------------------------------------------------
It's difficult to know yourself
It's easy to give advice to another
THALES OF MILETUS (Greek philoshopher)
MRNA trade ideas
HERCULES portfolio: weekly course valuationHERCULES’ mid-term trend chart is presented.
Also the mid-term trend charts of the stocks that make up the portfolio are presented. ___
Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile.
Disclaimer
The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only.
It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances,
it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
MRNA Reversal ConfirmedBounce off of the 20EMA yesterday (took calls yesterday, alerted in discord), flew right through previous resistance at 136. Long over this level, Targeting 146 next week, 160 end of month. Original SL below the 128, now trailing at 20%. 20EMA has still yet to cross, should see a pop if this reversal holds on the daily. Channel reversal confirmed could make MRNA a great long term hold!
Take a look MRNAWait for it, we are seeing strong pull back to 0.618 level, if pull back to 0.5 level there might be a chance to go long
RSI is signaling a good potential buy area, according to the historical comparison. let's see, let's see
Be aware this is not investment advice, for personal use only
MODERNA INC MRNA 1DThe market has been in a correction for two weeks, looks like everyday is a buying opportunity...
Let's see if it can keep this current level... Expiration on weekly option puts / calls also affect the stock price.
We'll see more upside once the correction is over. Long term target of $200 remains the same
$MRNA with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for $MRNA after a positive under reaction following its earnings release placing the stock in drift A
If you would like to see the Drift for another stock please message us. Also click on the Like Button if this was useful and follow us or join us.
variant/booster-shot playOpened a long position in $MRNA stock today. Could be a large head and shoulders pattern forming. Entry price in below the trend line & still got creamed today on volume & lack of market participation. Either way, baby was thrown out with the bath water. Other support levels will likely get this darling on an up swing by Friday or next Tuesday.
Ask yourself which vaccine you'd prefer - if given a choice...
Round Top Pattern. Greetings All,
Based on the rounding top pattern, I'm bearish on MRNA in the short-term. Target $116, which is also the 61.8% retracement level from the ATH ($189).
Happy Trading!
Disclaimer. My ideas are for informational purposes only. My ideas do not constitute solicitation, recommendation, endorsement, or offer to buy or sell any securities or other financial instruments. You should not construe any such information or other comments as legal, tax, investment, financial, or other advice. There are risks associated with investing in securities. Investing in stocks, bonds, exchange traded funds, mutual funds, options and money market funds involve risk of loss. Loss of principal is possible. Please exercise your own due diligence.
HERCULES portfolio: now it’s better to consist of cashHERCULES’ mid-term trend chart is presented. Also the mid-term trend charts of the stocks that make up the portfolio are presented. ___
Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile.
Disclaimer
The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only.
It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances,
it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
MRNA to 250 in MarMRNA could possibly reach as high as 250’s before or after the earnings report on 10 Mar.
Not only it may beat the earnings estimate, there are also quite positive news which may lead to explosive growth.
First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research
NEW YORK and LA JOLLA, CA—A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.
…
The study sets the stage for additional clinical trials that will seek to refine and extend the approach—with the long-term goal of creating a safe and effective HIV vaccine. As a next step, IAVI and Scripps Research are partnering with the biotechnology company Moderna to develop and test an mRNA-based vaccine that harnesses the approach to produce the same beneficial immune cells. Using mRNA technology could significantly accelerate the pace of HIV vaccine development.
…
The strategy of targeting naïve B cells with specific properties is called “germline-targeting,” as these young B cells display antibodies encoded by unmutated, or “germline” genes. Researchers believe the approach could also be applied to vaccines for other challenging pathogens such as influenza, dengue, Zika, hepatitis C viruses and malaria.
MRNA: the cup turns out to be a double top?MRNA’s mid-term trend chart is presented. ___
Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile.
Disclaimer
The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only.
It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances,
it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
HERCULES: weekly portfolio course valuationHERCULES’ mid-term trend chart is presented. ___
Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile.
Disclaimer
The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only.
It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances,
it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.